(Circulation. 2001;103:108.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
Elevation of Plasma High-Density Lipoprotein Concentration Reduces Interleukin-1–Induced Expression of E-Selectin in an In Vivo Model of Acute Inflammation
From the British Heart Foundation Cardiovascular Research Unit, National Heart and Lung Institute, Imperial College School of Medicine, Hammersmith Hospital Campus, London, UK (G.W.C., T.Y.H., A.W., C.S., D.O.H.); the ZLB Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland (P.G.L.); and the Department of Cardiovascular Biochemistry, St Bartholomew’s and the Royal School of Medicine and Dentistry, Queen Mary’s and Westfield College, London, UK (N.E.M.).
Correspondence to G.W. Cockerill, Department of Cardiovascular Biochemistry, St Bartholomew’s and the Royal London SMD, Queen Mary’s and Westfield College, Charterhouse Square, London EC1 M 6BQ, UK. E-mail g.w.cockerill{at}mds.qmw.ac.uk
Background—Although there is strong evidence that plasma HDL levels correlate inversely with the incidence of coronary artery disease, the precise mechanism(s) for the protective effect of HDLs remains unclear. We recently showed that HDLs inhibit endothelial cell expression of cytokine-induced leukocyte adhesion molecules in vitro. Our study therefore sought to test the hypothesis that elevating the level of circulating HDLs would inhibit endothelial cell activation in vivo.
Methods and Results—We
used a porcine model of inflammation previously established in our
laboratory, in which the level of vascular endothelial cell expression
of E-selectin in interleukin (IL)-1
–induced skin lesions was
measured by the uptake of a radiolabeled anti–E-selectin antibody
(1.2B6). Porcine plasma HDL levels were elevated by use of a bolus
injection of reconstituted discoidal HDL (recHDL). These particles
resemble nascent HDL particles in shape and contain apolipoprotein A-I
as the sole protein and soybean phosphatidylcholine as the sole
phospholipid. We found that recHDLs inhibited the expression of
IL-1–induced E-selectin by porcine aortic endothelial cells in
vitro, confirming that the inhibitory effect is conserved with
synthetic HDLs and demonstrating that the phenomenon is not restricted
to human endothelial cells. In vivo, elevating the circulating level of
HDLs 
2-fold led to significant inhibition of basal and
IL-1–induced E-selectin expression by porcine microvascular
endothelial cells.
Conclusions—These observations demonstrate the potential anti-inflammatory action of HDLs and provide support for the further investigation of the mechanisms underlying the inhibitory effects of HDLs on endothelial cell activation.
Key Words: inflammation • atherosclerosis • proteins • endothelium • apolipoproteins
This article has been cited by other articles:
 |
|
 |
|
  M. Tolle, A. Pawlak, M. Schuchardt, A. Kawamura, U. J. Tietge, S. Lorkowski, P. Keul, G. Assmann, J. Chun, B. Levkau, et al. HDL-Associated Lysosphingolipids Inhibit NAD(P)H Oxidase-Dependent Monocyte Chemoattractant Protein-1 Production Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1542 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Singh-Manoux, D. Gimeno, M. Kivimaki, E. Brunner, and M. G. Marmot Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II Study Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Robins, D. Collins, J. J. Nelson, H. E. Bloomfield, and B. F. Asztalos Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Van Linthout, F. Spillmann, A. Riad, C. Trimpert, J. Lievens, M. Meloni, F. Escher, E. Filenberg, O. Demir, J. Li, et al. Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy Circulation, March 25, 2008; 117(12): 1563 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Lim, T. Gayles, H. A. Katki, R. Stolzenberg-Solomon, S. J. Weinstein, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma Cancer Res., June 1, 2007; 67(11): 5569 - 5574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Scarmeas Invited Commentary: Lipoproteins and Dementia--Is It the Apolipoprotein A-I? Am. J. Epidemiol., May 1, 2007; 165(9): 993 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Barter Options for therapeutic intervention: how effective are the different agents? Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F47 - F53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter The role of HDL-cholesterol in preventing atherosclerotic disease Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F4 - F8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Nicholls, G. J. Dusting, B. Cutri, S. Bao, G. R. Drummond, K.-A. Rye, and P. J. Barter Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits Circulation, March 29, 2005; 111(12): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Barter Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2_suppl): S1 - S15. [Abstract] [PDF]
|
|
|
|
 |
|
 P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Bocharov, I. N. Baranova, T. G. Vishnyakova, A. T. Remaley, G. Csako, F. Thomas, A. P. Patterson, and T. L. Eggerman Targeting of Scavenger Receptor Class B Type I by Synthetic Amphipathic {alpha}-Helical-containing Peptides Blocks Lipopolysaccharide (LPS) Uptake and LPS-induced Pro-inflammatory Cytokine Responses in THP-1 Monocyte Cells J. Biol. Chem., August 20, 2004; 279(34): 36072 - 36082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Assmann and A. M. Gotto Jr HDL Cholesterol and Protective Factors in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-8 - III-14. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Liisanantti, M. L. Hannuksela, M. E. Ramet, and M. J. Savolainen Lipoprotein-Associated Phosphatidylethanol Increases the Plasma Concentration of Vascular Endothelial Growth Factor Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1037 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kaysen and J. P. Eiserich The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J Miller and R. Chacko The Role of Cholesterol and Statins in Alzheimer's Disease Ann. Pharmacother., January 1, 2004; 38(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Frank, H. Lee, D. S. Park, N. N. Tandon, P. E. Scherer, and M. P. Lisanti Genetic Ablation of Caveolin-1 Confers Protection Against Atherosclerosis Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 98 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calabresi, M. Gomaraschi, and G. Franceschini Endothelial Protection by High-Density Lipoproteins: From Bench to Bedside Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1724 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Thiemermann, N. S.A. Patel, E. O. Kvale, G. W. Cockerill, P. A.J. Brown, K. N. Stewart, S. Cuzzocrea, D. Britti, H. Mota-Filipe, and P. K. Chatterjee High Density Lipoprotein (HDL) Reduces Renal Ischemia/Reperfusion Injury J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1833 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Parolini, G. Chiesa, Y. Zhu, T. Forte, S. Caligari, E. Gianazza, M. G. Sacco, C. R. Sirtori, and E. M. Rubin Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. EVIDENCE OF APOA-IM IMPAIRED HEPATIC SECRETION J. Biol. Chem., February 7, 2003; 278(7): 4740 - 4746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Parhami, B. Basseri, J. Hwang, Y. Tintut, and L. L. Demer High-Density Lipoprotein Regulates Calcification of Vascular Cells Circ. Res., October 4, 2002; 91(7): 570 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. O'Connell and J. Genest Jr High-Density Lipoproteins and Endothelial Function Circulation, October 16, 2001; 104(16): 1978 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. COCKERILL, M. C. MCDONALD, H. MOTA-FILIPE, S. CUZZOCREA, N. E. MILLER, and C. THIEMERMANN High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock FASEB J, September 1, 2001; 15(11): 1941 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui and Z. Mallat Anti-Inflammatory Mechanisms in the Vascular Wall Circ. Res., May 11, 2001; 88(9): 877 - 887. [Abstract] [Full Text] [PDF]
|
|